Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by TriumphSpitSixon Nov 30, 2020 1:02am
205 Views
Post# 31998496

RE:RE:RE:RE:RE:Pfizer's anticipated approval of Tanezumab for OA

RE:RE:RE:RE:RE:Pfizer's anticipated approval of Tanezumab for OA100mg is still my target. The safety profile at this level would be unparalleled and if efficacy is even 75-80% of the "unpowered" 150mg dose it would still work well AND be an absolute rubber stamp for FDA approval. 

The unpowered-for-statistical-significance 150mg dose demonstrated a WOMAC score (39% reported pain reduction) that was only 5% lower than either the 200mg or the 250mg which both demonstrated a 44% reduction at 14 days. We know from anecdotal evidence in other NSAID trials that pain reduction continues to increase out to what, 6-8 weeks, so this number will continue to rise.

Safety is No. 1 for FDA approval. Cut efficacy a few percent to guarantee safety = WIN.



MrMugsy wrote: Correction on dosing ....

If we can prove out 150 mg ... that's 1/6.67 the naproxen (we have a chance).
If we can get to 125 mg ... 1/8 the naproxen (I will cross my fingers and bet on this one ... for fun!).
If we can get to 100 mg ... 1/10 the naproxen (I would not take this bet ... even I don't believe it and I've been extremely positive to this point).

: )


<< Previous
Bullboard Posts
Next >>